Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Doctors use three markers to help define breast cancers and guide treatment. One of those is the HER2 protein. The other two are hormone receptors (HR). When a cancer has none of these ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

I think in HER2+ breast cancer, it's much easier to do ... for a second opinion because they had had a circulating tumor marker, whether it was CEA, CA 15-3, or CA 27-29, that was above normal.

If enough tumor cells were collected during the FNA, we can also test for tumor markers. These breast cancer tumor markers include ER, PR, and HER2. They can help us predict how the cancer will ...

You have a critical role in determining your breast cancer treatment plan. Here’s how you can work with your doctor. According to the National Cancer Institute, hormone receptor–positive (HR ...

Systemic therapy is the main stay of management for metastatic breast cancer patients. Treatment is tailored to the tumor biology, hormone receptor status, HER2 expression and genetic markers like ...

Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...